Vitreomacular traction treatment now approved for use in Europe

Jetrea, an intravitreal injection therapy which was previously approved by the FDA last October, has now gained approval for use in Europe. Jetrea is the only approved drug therapy used to treat vitreomacular traction (VMT). Vitreomacular traction causes holes in the macula, which then leads to irreversible vision loss. The macula is responsible for central vision and affects daily activities such as driving and reading. It's believed that between 250,000 and 300,000 Europeans are affected by the condition. Jetrea works by targeting the protein fibers which cause the macular holes. Jetrea gives eye care professionals the option of treating VMT with a one-time injection rather than surgery.